Clinical Research Directory

Inclusion Criteria: * Subjects fully understand the purpose, content, process, and potential adverse events of the trial, voluntarily participate in the trial, and sign an informed consent form before any trial procedure begins. * Weight: 60\~72kg; Body mass index (BMI) ≥ 19 and ≤ 26 kg /m² for healthy Chinese male subjects. * Fasting LDL-C level\<4.1mmol/L. * Fasting triglycerides\<3.42mmol/L. * Required to voluntarily adopt effective contraceptive measures as specified in the protocol throughout the entire trial period and within 3 months after receiving the investigational product, and avoid sperm donation. Exclusion Criteria: * 12 months prior use of PCSK9 inhibitors treatment. * Allergic to the components of Ebronucimab and any monoclonal antibodies. * History of important organ transplantation (such as heart, lung, liver, kidney, etc.). * Abnormal vital signs during screening period and before randomization. * Investigators believe that other factors may disqualify individuals from participating in the trial.